A 24-week, Randomised, Open-label, Parallel-group, Multicentre Studywhich Compares the Efficacy and Safety of Rosuvastatin 10, 20 and 40 mgwith Atorvastatin 10, 20, 40 and 80 mg when Force-titrated in the Treatmentof Patients with Primary Hypercholesterolemia and Either a History ofCoronary Heart Disease (CHD) or Clinical Evidence of Atherosclerosis or aCHD Risk Equivalent (10-year Risk Score >20%)ECLIPSE - An Evaluation to Compare Lipid-lowering effects of rosuvastatin andatorvastatin In force-titrated patients: a Prospective Study of Efficacy and tolerability
Study identifier:D3569C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 24-week, Randomised, Open-label, Parallel-group, Multicentre Studywhich Compares the Efficacy and Safety of Rosuvastatin 10, 20 and 40 mgwith Atorvastatin 10, 20, 40 and 80 mg when Force-titrated in the Treatmentof Patients with Primary Hypercholesterolemia and Either a History ofCoronary Heart Disease (CHD) or Clinical Evidence of Atherosclerosis or aCHD Risk Equivalent (10-year Risk Score >20%)ECLIPSE - An Evaluation to Compare Lipid-lowering effects of rosuvastatin andatorvastatin In force-titrated patients: a Prospective Study of Efficacy and tolerability
Medical condition
hypercholesterolaemia
Phase
N/A
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
